Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2026—A study of 830 children with pediatric central nervous system tumors found that 23.3% carried germline pathogenic variants in cancer predisposition genes, impacting tumor development and outcomes. Another study identified pathogenic variants in 13.2% of infertile women experiencing IVF/ICSI failures, with TUBB8 being the most frequently mutated gene.
February 2026
Q. Why aren’t more medical students interested in applying for a pathology residency? Read answer.
Q. What is your opinion on employing qualitative rapid homogeneous immunoassay (enzyme-multiplied immunoassay technique, ELISA) urine screens for tricyclic antidepressant (TCA) testing in pregnant women and emergencies involving neonates, particularly at a low cutoff threshold of 300 ng/mL? Read answer.
February 2026—Vega Health, founded by Dr. Mark Sendak, aims to democratize AI-based healthcare solutions by providing small to mid-sized health systems with access to proven AI innovations developed by healthcare professionals.
February 2026—CAP TODAY publisher Bob McGonnagle spoke on Dec. 2, 2025 with Steve Swartzell and Scott Johnston of ELITechGroup. McGonnagle’s questions and their answers follow. A few of the questions came from the roundtable audience and are identified as such.
Bob McGonnagle: Steve, how long have you been with ELITech and what is your background in molecular diagnostics?
Steve Swartzell: I am director of customer experience and have been with ELITechGroup for 22 years. My background is in microbiology. I started as a research scientist in R&D and I was an application specialist working directly with customers. I have many years of lab experience as well. Now I oversee all the field activities for ELITechGroup MDx in the U.S. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ELITechGroup.
February 2026—The CAP supports the FDA’s proposal to reclassify oncology therapeutic nucleic-acid-based test systems from class III to class II devices with 510(k) requirements.
